106 related articles for article (PubMed ID: 17504511)
1. A polymorphism in FAS gene promoter correlated with circulating soluble FAS levels.
Mahfoudh W; Bel Hadj Jrad B; Romdhane A; Chouchane L
Int J Immunogenet; 2007 Jun; 34(3):209-12. PubMed ID: 17504511
[TBL] [Abstract][Full Text] [Related]
2. The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis.
Liakouli V; Manetti M; Pacini A; Tolusso B; Fatini C; Toscano A; Cipriani P; Guiducci S; Bazzichi L; Codullo V; Ruocco L; Dell'orso L; Carubbi F; Marrelli A; Abbate R; Bombardieri S; Ferraccioli G; Montecucco C; Valentini G; Matucci-Cerinic M; Ibba-Manneschi L; Giacomelli R
Ann Rheum Dis; 2009 Apr; 68(4):584-90. PubMed ID: 18445624
[TBL] [Abstract][Full Text] [Related]
3. A polymorphism in FAS gene promoter associated with increased risk of nasopharyngeal carcinoma and correlated with anti-nuclear autoantibodies induction.
Bel Hadj Jrad B; Mahfouth W; Bouaouina N; Gabbouj S; Ahmed SB; Ltaïef M; Jalbout M; Chouchane L
Cancer Lett; 2006 Feb; 233(1):21-7. PubMed ID: 16473667
[TBL] [Abstract][Full Text] [Related]
4. FAS -670A>G promoter polymorphism is associated with soluble Fas levels in primary Sjögren's syndrome.
Treviño-Talavera BA; Palafox-Sánchez CA; Muñoz-Valle JF; Orozco-Barocio G; Navarro-Hernández RE; Vázquez-Del Mercado M; García de la Torre I; Oregon-Romero E
Genet Mol Res; 2014 Jul; 13(3):4831-8. PubMed ID: 25062418
[TBL] [Abstract][Full Text] [Related]
5. Fas gene polymorphisms in systemic lupus erythematosus and serum levels of some apoptosis-related molecules.
Arasteh JM; Sarvestani EK; Aflaki E; Amirghofran Z
Immunol Invest; 2010; 39(1):27-38. PubMed ID: 20064083
[TBL] [Abstract][Full Text] [Related]
6. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus.
Kanemitsu S; Ihara K; Saifddin A; Otsuka T; Takeuchi T; Nagayama J; Kuwano M; Hara T
J Rheumatol; 2002 Jun; 29(6):1183-8. PubMed ID: 12064832
[TBL] [Abstract][Full Text] [Related]
7. Association between FAS polymorphism and prostate cancer development.
Lima L; Morais A; Lobo F; Calais-da-Silva FM; Calais-da-Silva FE; Medeiros R
Prostate Cancer Prostatic Dis; 2008; 11(1):94-8. PubMed ID: 17667965
[TBL] [Abstract][Full Text] [Related]
8. Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease.
Takabatake N; Nakamura H; Inoue S; Terashita K; Yuki H; Kato S; Yasumura S; Tomoike H
Respir Med; 2000 Dec; 94(12):1215-20. PubMed ID: 11192958
[TBL] [Abstract][Full Text] [Related]
9. No association between Fas A/G polymorphism and therapeutic effects induced by methimazole treatment for Graves' disease in Northern Chinese.
Li P; Li Q; Chen L; Sun Y; Zhang J
Pharmazie; 2008 Oct; 63(10):748-50. PubMed ID: 18972838
[TBL] [Abstract][Full Text] [Related]
10. Fas promoter region gene polymorphism is associated with an increased risk for myocardial infarction.
Hanasaki H; Takemura Y; Fukuo K; Ohishi M; Onishi M; Yasuda O; Katsuya T; Awata N; Kato N; Ogihara T; Rakugi H
Hypertens Res; 2009 Apr; 32(4):261-4. PubMed ID: 19262492
[TBL] [Abstract][Full Text] [Related]
11. Serum soluble fas level as a prognostic factor in patients with gynecological malignancies.
Konno R; Takano T; Sato S; Yajima A
Clin Cancer Res; 2000 Sep; 6(9):3576-80. PubMed ID: 10999747
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Fas gene promoter polymorphism in cervical cancer patients.
Dybikowska A; Sliwinski W; Emerich J; Podhajska AJ
Int J Mol Med; 2004 Sep; 14(3):475-8. PubMed ID: 15289903
[TBL] [Abstract][Full Text] [Related]
13. Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia.
Farre L; Bittencourt AL; Silva-Santos G; Almeida A; Silva AC; Decanine D; Soares GM; Alcantara LC; Van Dooren S; Galvão-Castro B; Vandamme AM; Van Weyenbergh J
J Leukoc Biol; 2008 Jan; 83(1):220-2. PubMed ID: 17962369
[TBL] [Abstract][Full Text] [Related]
14. Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain-Barre syndrome.
Geleijns K; Laman JD; van Rijs W; Tio-Gillen AP; Hintzen RQ; van Doorn PA; Jacobs BC
J Neuroimmunol; 2005 Apr; 161(1-2):183-9. PubMed ID: 15748958
[TBL] [Abstract][Full Text] [Related]
15. Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer.
Jain M; Kumar S; Lal P; Tiwari A; Ghoshal UC; Mittal B
Cancer Detect Prev; 2007; 31(3):225-32. PubMed ID: 17561354
[TBL] [Abstract][Full Text] [Related]
16. Lack of association between juvenile idiopathic arthritis and fas gene polymorphism.
Donn R; Zeggini E; Shelley E; Ollier W; Thomson W;
J Rheumatol; 2002 Jan; 29(1):166-8. PubMed ID: 11824955
[TBL] [Abstract][Full Text] [Related]
17. Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment.
Pignataro L; Arisi E; Sambataro G; Corsi MM
J Surg Oncol; 2003 Jun; 83(2):112-5. PubMed ID: 12772205
[TBL] [Abstract][Full Text] [Related]
18. [Analyzing of Fas-670 gene polymorphism in hepatocarcinoma tissue].
Zhang J; Liu Q; Mao HT
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):630-1. PubMed ID: 19719928
[No Abstract] [Full Text] [Related]
19. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.
Tinazzi E; Puccetti A; Gerli R; Rigo A; Migliorini P; Simeoni S; Beri R; Dolcino M; Martinelli N; Corrocher R; Lunardi C
Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929
[TBL] [Abstract][Full Text] [Related]
20. Polymorphism of Fas and Fas ligand in preterm premature rupture of membranes in singleton pregnancies.
Fuks A; Parton LA; Polavarapu S; Netta D; Strassberg S; Godi I; Hsu CD
Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):1132-6. PubMed ID: 16157125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
